A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953; NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor; Rhabdomyosarcoma; Neuroblastoma; Pleuropulmonary Blastoma; Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma